Ani Pharmaceuticals (ANIP) Cash & Equivalents (2010 - 2026)
Ani Pharmaceuticals (ANIP) posted Cash & Equivalents of $311.2 million for Q1 2026, up 8.96% sequentially from $285.6 million in Q4 2025, and up 107.72% YoY from $149.8 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Cash & Equivalents (2010 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Cash & Equivalents for 17 years, with the latest figure at $311.2 million in Q1 2026.
- Quarterly Cash & Equivalents rose 107.72% year-over-year to $311.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $311.2 million (up 107.72% YoY) and the FY2025 annual result came in at $285.6 million, up 97.14% from the prior year.
- Cash & Equivalents climbed to $311.2 million in Q1 2026 per ANIP's latest filing, from $285.6 million in the prior quarter.
- Over five years, Cash & Equivalents peaked at $311.2 million in Q1 2026 and troughed at $48.2 million in Q4 2022.
- A 5-year average of $169.1 million and a median of $161.7 million in 2023 frame the typical range for Cash & Equivalents.
- The sharpest annual moves came in 2022 and 2023: Cash & Equivalents tumbled 51.92% in 2022, then soared 358.49% in 2023.
- Over 5 years, Cash & Equivalents stood at $48.2 million in 2022, then surged by 358.49% to $221.1 million in 2023, then slumped by 34.49% to $144.9 million in 2024, then surged by 97.14% to $285.6 million in 2025, then grew by 8.96% to $311.2 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $311.2 million, $285.6 million, and $262.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | 1.11 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 3.66 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 1.48 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.89 Bn |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 1.80 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 886.50 Mn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 332.40 Mn |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 530.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 164.00 Mn |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 360.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 360.21 Mn |
| Mar 31, 2026 | 311.18 Mn |
| Dec 31, 2025 | 285.59 Mn |
| Sep 30, 2025 | 262.61 Mn |
| Jun 30, 2025 | 217.80 Mn |
| Mar 31, 2025 | 149.80 Mn |
| Dec 31, 2024 | 144.86 Mn |
| Sep 30, 2024 | 144.98 Mn |
| Jun 30, 2024 | 240.11 Mn |
| Mar 31, 2024 | 228.60 Mn |
| Dec 31, 2023 | 221.12 Mn |
| Sep 30, 2023 | 193.08 Mn |
| Jun 30, 2023 | 161.71 Mn |
| Mar 31, 2023 | 67.76 Mn |
| Dec 31, 2022 | 48.23 Mn |
| Sep 30, 2022 | 56.28 Mn |
| Jun 30, 2022 | 63.39 Mn |
| Mar 31, 2022 | 76.91 Mn |
| Dec 31, 2021 | 100.30 Mn |
| Sep 30, 2021 | 15.25 Mn |